Back to discover

Protein / target

Atrial natriuretic peptide receptor 2

Encoded byNPR2P20594Homo sapiensSwiss-Prot
UniProt: P20594Ensembl: ENSG00000159899HGNC: HGNC:7944NCBI Gene: 4882
Clinically validated
Therapeutic maturity
2
Approved medicines
Open Targets target-level
View by indication →
10
Clinical trials
Small-molecule tractable
Druggability
Druggable Family

Protein at a glance

Biological role

Natriuretic peptide receptor

Strongest disease association

Familial focal epilepsy with variable foci

Via encoding gene NPR2 · Genetic evidence · score 0.63

Therapeutic position

Established drug target

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for the C-type natriuretic peptide NPPC/CNP hormone.

View complete UniProt function annotation

Receptor for the C-type natriuretic peptide NPPC/CNP hormone. Has guanylate cyclase activity upon binding of its ligand. May play a role in the regulation of skeletal growth

Subcellular location

Cell membrane
Domains and Gene Ontology detail (61)

Domains & features

Protein kinaseGuanylate cyclase

Gene Ontology

  • Ccilium
  • Ccytoplasm
  • Cneuron projection
  • Cnucleus
  • Cplasma membrane
  • Csynapse
  • FATP binding
  • FGTP binding
  • Fguanylate cyclase activity
  • Fhormone binding
  • Fidentical protein binding
  • Fnatriuretic peptide receptor activity

1047 aa · 117 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingGOGrowth-factor signallingGO
View supporting evidence

Synaptic signalling

  • ·synapse
  • ·chemical synaptic transmission

Growth-factor signalling

  • ·epidermal growth factor receptor signaling pathway
  • ·response to fibroblast growth factor

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 1 area

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Bone Diseases1 medicine
vosoritide

2 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

vosoritide
Narrow target profileApprovedBinding agent

Atrial natriuretic peptide receptor B binding agent

Indicated for Bone Diseases

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene NPR2

Gene-level evidence surfaced through the gene NPR2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Achondroplasia
0.75Well supported

Clinical evidence dominant · Open Targets 0.57

Familial focal epilepsy with variable foci
0.63Moderately supported

Genetic evidence dominant · Open Targets 0.38

Genetic Diseases, Inborn
0.62Moderately supported

Genetic evidence dominant · Open Targets 0.38

Heart Failure
0.49Limited support

Clinical evidence dominant · Open Targets 0.39

Bone Diseases
0.46Limited support

Clinical evidence dominant · Open Targets 0.37

View evidence synthesis (5)
AchondroplasiaWell supported
0.75
agreement 0.62–0.88
Clinical75%Animal model22%Literature3%

Open Targets aggregate 0.57 · 3 independent evidence families

Familial focal epilepsy with variable fociModerately supported
0.63
agreement 0.51–0.74
Genetic100%

Open Targets aggregate 0.38 · 1 independent evidence family

Genetic Diseases, InbornModerately supported
0.62
agreement 0.48–0.76
Genetic99%Literature1%

Open Targets aggregate 0.38 · 2 independent evidence families

Heart FailureLimited support
0.49
agreement 0.33–0.64
Clinical97%Literature3%

Open Targets aggregate 0.39 · 2 independent evidence families

Bone DiseasesLimited support
0.46
agreement 0.30–0.61
Clinical99%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Achondroplasia0.57
Heart Failure0.39
Familial focal epilepsy with variable foci0.38
Genetic Diseases, Inborn0.38
Bone Diseases0.37

Drug development

2 compounds recorded · 2 approved

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (2)
CARPERITIDEApproval
VOSORITIDEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Emerging

Feasibility evidence (druggable family) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

Other modalities — Strong

Approved Drug support this modality.

View underlying tractability evidence (7)
SM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life DataOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

10

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPHASE2/PHASE3

RECRUITING · via vosoritide · NCT07441876

A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With HypochondroplasiaPHASE3

ENROLLING_BY_INVITATION · via vosoritide · NCT07073014

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children With HypochondroplasiaPHASE3

ACTIVE_NOT_RECRUITING · via vosoritide · NCT06455059

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 MonthsPHASE2

RECRUITING · via vosoritide · NCT07126262

View all trials (6)
A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentPHASE2

RECRUITING · via vosoritide · NCT06668805

A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short StaturePHASE2

RECRUITING · via vosoritide · NCT06382155

Vosoritide for Treatment of Short Stature in Girls With Turner SyndromePHASE2

RECRUITING · via vosoritide · NCT05849389

A Proof of Concept Study to Evaluate the Safety and Efficacy of Voxzogo (Vosoritide) for the Treatment of Growth Deficits in MPS IVA and VIPHASE1/PHASE2

ACTIVE_NOT_RECRUITING · via vosoritide · NCT05845749

A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression SurgeryPHASE2

ACTIVE_NOT_RECRUITING · via vosoritide · NCT04554940

Vosoritide for Selected Genetic Causes of Short StaturePHASE2

ACTIVE_NOT_RECRUITING · via vosoritide · NCT04219007

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2021-08-26

    Approval: Voxzogo (EMA)

    ema · regulatory · ema · via vosoritide

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.